Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | NT5E | P21589 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.73 |
| ▸ | DPP4 | P27487 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.72 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.72 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.72 |
| ▸ | GAPDH | P04406 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | STAT6 | P42226 | 1/20 | 0.72 |
| ▸ | PI4KA | P42356 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7168927 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL114918 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL20419174 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL972926 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL16579288 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL24359132 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL114917 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL10176676 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL22559823 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL10159432 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223173-B1 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | EP | claimed |
| EP-0651759-B1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS INC (US) | 2003-12-10 | — | — | EP | claimed |
| US-6624294-B2 | Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside | ISIS PHARMACEUTICALS, INC. | 2003-09-23 | — | — | US | claimed |
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | IONIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | claimed |
| EP-1223173-A2 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | claimed |
| US-6355472-B2 | ACID PHOSPHATASE | AJINOMOTO CO., INC. (JP) | 2002-03-12 | — | — | US | claimed |
| US-20020004590-A1 | Method for producing nucleoside-5'-phosphate ester | MIHARA YASUHIRO (JP) | 2002-01-10 | — | — | US | claimed |
| US-6207435-B1 | MUTANT ACID PHOSPHATASE HAVING DECREASED MICHAELIS CONSTANT FOR A NUCLEOSIDE AND/OR INCREASED TEMPERATURE STABILITY; FOR EFFICIENT PHOSPHORYLATION OF NUCLEOSIDES TO PRODUCE NUCLEOTIDES | AJINOMOTO CO., INC. (JP) | 2001-03-27 | — | — | US | claimed |
| US-6015697-A | ECONOMICAL AND EFFICIENT PROCESS BY REACTING A NUCLEOSIDE WITH A PHOSPHATE DONOR GROUP IN PRESENCE OF MUTANT ACID PHOSPHATASE WITH DECREASED MICHAELIS CONSTANT FOR NUCLEOSIDE OR INCREASED TEMPERATURE STABILITY | AJINOMOTO CO., INC. (JP) | 2000-01-18 | — | — | US | claimed |
| US-5856466-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | claimed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | claimed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | claimed |
| US-5474929-A | Adenosine deaminase gene | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1995-12-12 | — | — | US | claimed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | claimed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | claimed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | claimed |
| JP-10087689-A | — | — | None | — | — | JP | disclosed |
| EP-4717773-A2 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES | Silence Therapeutics GmbH (DE) | 2026-04-01 | — | — | EP | disclosed |
| WO-1986005518-A1 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |
| WO-1986005519-A1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | NSUN2, NT5C3B, RNGTT | LMNA 496/4885NT5E 92/4885HIF1A 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.